Evoke Financial Statements From 2010 to 2025

EVOK Stock  USD 3.16  0.33  9.46%   
Evoke Pharma financial statements provide useful quarterly and yearly information to potential Evoke Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Evoke Pharma financial statements helps investors assess Evoke Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Evoke Pharma's valuation are summarized below:
Gross Profit
9.9 M
Profit Margin
(0.52)
Market Capitalization
5.7 M
Enterprise Value Revenue
0.0459
Revenue
10.2 M
There are currently one hundred twenty fundamental signals for Evoke Pharma that can be evaluated and compared over time across rivals. We recommend to verify Evoke Pharma's prevailing fundamental drivers against the all of the trends between 2010 and 2025. The value of Market Cap is estimated to slide to about 8 M. Enterprise Value is expected to rise to about (12.8 T) this year

Evoke Pharma Total Revenue

10.76 Trillion

Check Evoke Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evoke Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 151.4 K, Interest Expense of 526.4 B or Selling General Administrative of 13.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0. Evoke financial statements analysis is a perfect complement when working with Evoke Pharma Valuation or Volatility modules.
  
Check out the analysis of Evoke Pharma Correlation against competitors.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.

Evoke Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets18.4 T17.5 T2.2 T
Slightly volatile
Other Current Liabilities10.8 T10.3 T1.3 T
Slightly volatile
Total Current Liabilities10.9 T10.4 T1.3 T
Slightly volatile
Accounts Payable1.3 MM1.2 M
Slightly volatile
Cash14.3 T13.6 T1.7 T
Slightly volatile
Cash And Short Term Investments14.3 T13.6 T1.7 T
Slightly volatile
Common Stock Total Equity3.2 K3.1 K1.6 K
Slightly volatile
Common Stock Shares OutstandingM1.9 M727.2 K
Slightly volatile
Liabilities And Stockholders Equity18.4 T17.5 T2.2 T
Slightly volatile
Other Current Assets814.6 B775.8 B99.4 B
Slightly volatile
Other Stockholder Equity142.6 T135.8 T17.4 T
Slightly volatile
Total Liabilities11 T10.5 T1.3 T
Slightly volatile
Total Current Assets18.1 T17.2 T2.2 T
Slightly volatile
Common Stock156.4 M149 M19.1 M
Slightly volatile
Short and Long Term Debt Total168.5 B160.5 B20.6 B
Slightly volatile
Other Liabilities1.3 MM1.3 M
Very volatile
Non Current Assets Total295.2 B281.1 B36 B
Slightly volatile
Other Assets81.5 K137.9 K197.5 K
Slightly volatile
Long Term Debt Total4.1 M5.8 MM
Slightly volatile
Capital Surpluse74.9 M110 M71.8 M
Slightly volatile
Short Term Debt62.5 B59.5 B7.6 B
Slightly volatile
Short and Long Term DebtM5.8 M1.8 M
Slightly volatile
Non Current Liabilities Other96.6 K101.7 K2.1 M
Slightly volatile
Net Invested Capital5.1 M2.8 M3.5 M
Slightly volatile
Net Working Capital6.1 M4.4 M5.6 M
Very volatile
Capital Stock2863011.6 K
Slightly volatile
Net Receivables2.5 T2.4 T310.1 B
Slightly volatile

Evoke Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative13.3 M12.7 M5.8 M
Slightly volatile
Other Operating Expenses16.2 T15.5 TT
Slightly volatile
Research Development17.1 B16.3 B2.1 B
Slightly volatile
Total Operating Expenses16.2 T15.5 TT
Slightly volatile
Interest Income74.9 K130.2 K160.2 K
Slightly volatile

Evoke Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation811.8 B773.1 B99.1 B
Slightly volatile
Begin Period Cash FlowT4.7 T607.2 B
Slightly volatile
End Period Cash Flow14.3 T13.6 T1.7 T
Slightly volatile
Sale Purchase Of Stock102.1 K107.5 K8.6 M
Slightly volatile
Change To Netincome1.6 M1.7 M1.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.00.0K
Slightly volatile
Days Sales Outstanding14586.1938281
Slightly volatile
Average Payables603.1 KM744.9 K
Slightly volatile
Stock Based Compensation To Revenue0.07170.075448.7692
Slightly volatile
Inventory Turnover0.460.480.5276
Slightly volatile
Days Of Inventory On Hand648K873
Slightly volatile
Payables Turnover0.20.110.1237
Slightly volatile
Research And Ddevelopement To Revenue0.00150.0016196
Slightly volatile
Capex To Revenue0.00.00.0
Slightly volatile
Cash Per Share7.5 M7.1 M914.6 K
Slightly volatile
Days Payables Outstanding2.8 K3.6 K4.4 K
Slightly volatile
Income Quality0.991.01990.9212
Pretty Stable
Current Ratio1.581.66074.1486
Pretty Stable
Receivables Turnover3.584.23462.2419
Slightly volatile
Capex Per Share0.00.00.0
Slightly volatile
Average Receivables1.3 T1.2 T155.1 B
Slightly volatile
Revenue Per Share5.6 M5.4 M689.3 K
Slightly volatile
Debt To Assets0.00870.00921.7798
Slightly volatile
Operating Cycle81.8886.1938K
Slightly volatile
Days Of Payables Outstanding2.8 K3.6 K4.4 K
Slightly volatile
Ebt Per Ebit0.821.02841.0111
Pretty Stable
Quick Ratio1.541.61784.1192
Pretty Stable
Net Income Per E B T0.810.890.9819
Slightly volatile
Cash Ratio1.241.30993.8115
Pretty Stable
Days Of Inventory Outstanding648K873
Slightly volatile
Days Of Sales Outstanding14586.1938281
Slightly volatile
Fixed Asset Turnover43.2659.8320.0615
Slightly volatile
Debt Ratio0.00870.00921.7798
Slightly volatile
Price Sales Ratio0.00.0K
Slightly volatile
Asset Turnover0.610.5850.145
Slightly volatile

Evoke Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapM8.4 M73.9 M
Slightly volatile

Evoke Fundamental Market Drivers

Cash And Short Term Investments13.6 T

Evoke Upcoming Events

19th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Evoke Pharma Financial Statements

Evoke Pharma investors utilize fundamental indicators, such as revenue or net income, to predict how Evoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-4.5 M-4.7 M
Total Revenue10.2 T10.8 T
Cost Of Revenue232.2 K243.8 K
Stock Based Compensation To Revenue 0.08  0.07 
Revenue Per Share5.4 M5.6 M
Ebit Per Revenue(0.51)(0.53)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock:
Check out the analysis of Evoke Pharma Correlation against competitors.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(10.13)
Revenue Per Share
5.38
Quarterly Revenue Growth
0.974
Return On Assets
(0.26)
Return On Equity
(2.40)
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.